drugset / Trial / NCT01703078

Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis

NCT01703078 ↗

Phase 1 Completed 41 enrolled LEO Pharma
RandomizedSingle-groupSingle-blindTreatment

Summary

The purpose of this study is to determine if the new ingenol derivative gels are as safe as and as well tolerated as ingenol mebutate gel when applied to AK lesions on the forearm for two consecutive days.

Timeline

Start
2012-11
Primary completion
2013-03
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ingenol Small molecule 0.05 % Topical

Indications